MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted and concluded that DiaMedica “may proceed” with the proposed clinical investigation using its amended protocol adding stroke […]
Author: Ken Dropiewski
Shockwave Medical Unveils First One-Year Results of Coronary Intravascular Lithotripsy
New Data at TCT From the Disrupt CAD Clinical Program Demonstrate Consistency of Shockwave IVL Outcomes Over Time, Across Calcium Morphologies and Between Genders November 05, 2021 08:00 ET | Source: Shockwave Medical, Inc. SANTA CLARA, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the […]
CVRx Reports Third Quarter 2021 Financial and Operating Results
Third Quarter 2021 Revenue of $3.4 million, a 241% Increase Over Prior Year MINNEAPOLIS, Nov. 04, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced its […]
Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint
WINNIPEG, MB, Nov. 4, 2021 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the results from the SAVI-PCI clinical trial demonstrating that the use of short infusion AGGRASTAT® (tirofiban hydrochloride) injection was non-inferior to label-dosing INTEGRILIN® (eptifibatide) or long-infusion AGGRASTAT® in a primary […]
Angel Medical Systems Announces Mike Gillem as Chief Commercial Officer
EATONTOWN, N.J., Nov. 5, 2021 /PRNewswire/ — Angel Medical Systems, Inc., (DBA AngelMed) announced today the appointment of Mike Gillem as Chief Commercial Officer. Mike will be responsible for the direction and management of all sales and marketing activities for The Guardian System, the company’s premier cardiac monitoring product. Mike brings more than 29 years […]
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This analysis from the PARTNER 3 trial was presented during the […]
CryoLife Reports Third Quarter 2021 Financial Results
ATLANTA, Nov. 4, 2021 /PRNewswire/ — Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in […]
iRhythm Technologies Announces Third Quarter 2021 Financial Results
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended September 30, 2021. Third Quarter 2021 Financial Highlights Revenue was $85.4 million, a 18.7% increase […]
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated […]
Acceleron Reports Third Quarter 2021 Financial Results
– Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) – – Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition scheduled for December 11 to […]



